

A *Trichosporon asahii* Bloodstream Infection in a Preterm Newborn with a Successful Outcome: A Case Report

Bukhari MA^{4*}, Abdelrazek SAM^{1,2}, Abeer H El-Shalakany^{2,3} and Faiz A²

¹Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt

²Microbiology Unit, Laboratory of Maternity and Children Hospital, Makkah, Saudi Arabia

³Department of Clinical Pathology, Faculty of Medicine, El-Menoufia University, El-Menoufia, Egypt

⁴Public Health Laboratory, Makkah, Saudi Arabia

Abstract

Trichosporon asahii is a rare opportunistic fungal pathogen that causes fatal systemic infections in immunocompromised patients. We have reported a case of *T. asahii* fungemia in a low birth weight preterm newborn baby in the neonatal intensive care unit (NICU). This case of *T. asahii* fungemia was unresponsive to treatment with a combination of Amphotericin B and Fluconazole. However, Treatment with a combination of Voriconazole and Caspofungin was successfully eliminated the fungus from the blood of the infected patient.

Keywords: *Trichosporon asahii*; Bloodstream infection; Preterm newborn

Background

The mortality rate among patients with fungal bloodstream infection is high, ranging from 50% to 80% [1]. *Candida* species are usually susceptible to standard antifungal agents. Whereas, the treatment of non-candida yeasts is more difficult because they have innate resistance to standard antifungal agents which limits treatment options [2]. *Trichosporon asahii* (previously known as *T. beigelii*) is an emerging, opportunistic non-candida yeast pathogen that causes superficial dermatologic infections (white piedra and onychomycosis) in immunocompetent individuals, however, among immunocompromised patients, it causes severe complications, disseminated disease with poor prognosis and fatal infections for neonatal [3]. Prematurity is an important predisposing factors for invasive *Trichosporon* infections [4].

Case presentation

A 30 weeks, low birth weight (about 1500 g), preterm girl baby was delivered by Cesarean Section (due to maternal antepartum hemorrhage) in the Maternity and Children Hospital, Makkah, Saudi Arabia. Immediately after delivery, the baby suffered from respiratory distress and cardiac arrest and lifesaving resuscitation was done successfully and the baby was admitted to the Nursery Intensive Care Unit (NICU) where the baby developed manifestations of pneumothorax, for which, emergency intercostal drainage tube, high frequency ventilation, central venous catheter, as well as a prophylactic course of broad-spectrum antibiotics were necessary with subsequent recovery. In the NICU, *T. asahii* was isolated from the baby nasal swab culture on the 19th day of life. On 21st day it was isolated from both nasal and groin swabs. On 27th day, *T. asahii* was isolated from blood culture for the first time and treatment started using Amphotericin B and Fluconazole. No specific clinical manifestations were recognized on the preterm baby.

Despite of the treatment, The fungus continued to be isolated again from blood cultures on 29th, 34th, 37th, 43rd, 50th, 54th, 59th days. On the 60th day, Amphotericin B and Fluconazole were replaced by a combination of Voriconazole and Caspofungin. From the 74th day of life and onward, *T. asahii* could not be isolated from blood cultures. Routine laboratory investigations were within normal values for anemia (Hemoglobin: 8.7 g/dL), thrombocytopenia (Platelets: 70,000/

μL), prolonged prothrombin time (PT: 17 seconds), metabolic and respiratory acidosis. For the isolation of *T. asahii*, blood culture bottles were incubated inside the automated Bact/Alert blood culture System (BacT/ALERT® 3D; BioMérieux, Marcy-l'Etoile, France). On positive signal, blood samples from positive bottles were examined directly under light microscope (oil lens X 1000) and showed yeast like fungi and elongated blastoconidia. In the same time, blood samples from positive bottles were cultured on Sabouraud's dextrose agar (SDA), blood agar and chocolate agar (nasal and groin swabs were cultured on the same media). After 48 h of incubation at 37°C, colonies of yeast-like fungi were isolated. Even though, colonies needed 7 days at 37°C to reach the characteristic white, rosette- shaped, wrinkled colonies with radiating furrows and umbonate centers.

Microscopic examination of gram-stained smears of these colonies, demonstrated round to oval, budding yeast-like cells, elongated blastoconidia, septate pseudohyphae and cylindrical arthroconidia. Identification of the isolate as *T. asahii* as well as antifungal susceptibility testing were done by the Vitek 2 automated system (BioMerieux, Marcy l'Etoile, France) using the card kits for yeast identification (YST) and sensitivity (AST-YS07). Minimum Inhibitory Concentrations (MICs) were as follows: Amphotericin B 2 μg/mL; Fluconazole 1 μg/mL; Voriconazole ≤ 0.12 μg/mL; Micafungin ≤ 0.06 μg/mL; Caspofungin ≤ 0.25 μg/mL and Flucytosine ≤ 1 μg/mL (Figures 1 and 2).

Discussion

Over the last two decades, *Trichosporon* species have been increasingly reported as opportunistic pathogens that can cause invasive infections. *Trichosporon* species were isolated from different types of clinical specimens, including blood, urine and skin specimens. Moreover, they were recognized in colonization of the gastrointestinal

*Corresponding author: Bukhari MA, Microbiology Unit, Public Health Laboratory, Makkah, Saudi Arabia, Tel: +20 127 811 5568; E-mail: mamkb@hotmail.com

Received February 05, 2017; Accepted February 21, 2017; Published February 27, 2017

Citation: Bukhari MA, Abdelrazek SAM, El-Shalakany AH, Faiz A (2017) A *Trichosporon asahii* Bloodstream Infection in a Preterm Newborn with a Successful Outcome: A Case Report. J Blood Lymph 7: 157. doi: [10.4172/2165-7831.1000157](https://doi.org/10.4172/2165-7831.1000157)

Copyright: © 2017 Bukhari MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Figure 1: Direct microscopic examination of blood sample from positive blood culture bottles show oval elongated yeast-like cells, elongated blastoconidia of *T. asahii* (light microscope oil lens X 1000).



Figure 2: *T. asahii* colonies on SDA after incubation at 37°C for 7 days.

tract, skin, mucosal surfaces, sputum, central venous catheter, stool, and hair. Six *Trichosporon* species (*T. asahii*, *T. asteroides*, *T. cutaneum*, *T. inkin*, *T. mucoides*, and *T. ovoides*) cause superficial and/or invasive infections. *T. asahii* is the most frequent *Trichosporon* species involved in disseminated human infections [5-10]. To date, only few cases of *Trichosporon asahii* fungemia were reported in Saudi Arabia [11]. In the present case, *T. asahii* was isolated from nasal and groin swabs before the isolation from blood cultures. This is consistent with a study by Yamamoto et al. [12] who found that colonization by the causative organisms prior to fungemia onset was noted in 72.7% of non-*Candida* fungemia patients. These findings could be important for predicting the occurrence of non-*Candida* fungemia. In addition, it might be important for prescribing prophylactic treatment with systemic suitable antifungal agents once the fungus is isolated from peripheral swabs.

The most common reported predisposing risk factors of invasive *T. asahii* infection included malignancies (mainly hematological malignancies with marked neutropenia), central venous catheters, prematurity with low birth weight, admission to intensive care units, administration of immunosuppressive agents, prior use of broad-spectrum antibiotics, Corticosteroid therapy, organ failure, organ transplantation, prosthetic valve surgery, HIV infection, extensive burns and peritoneal dialysis [13]. In the current case, several predisposing factors (in addition to prior colonization by the causative organism) may have acted singly or collectively for predisposition to bloodstream infection with *T. asahii*, namely, prematurity and low birth weight, central venous catheter, parenteral nutrition, insertion of intercostal drainage tube and the prior prophylactic course of broad spectrum antibiotics. However, in our case, Prematurity and low birth

weight are thought to be the main factors that facilitated colonization and subsequent sepsis of the preterm baby because of the deficiency of normal flora that competes with the opportunistic pathogens and by the fact that components of body defense systems are still immature enough in the preterm babies especially those with low birth weight.

In the present case of *T. asahii* fungemia, no specific clinical manifestations were registered on the preterm baby, however, regarding the laboratory investigations, there were anemia, thrombocytopenia, prolonged prothrombin time, metabolic and respiratory acidosis. Our results are nearly consistent with a previous case study by Pereira et al., [14,15] who reported anemia, thrombocytopenia and metabolic acidosis in a low birth weight preterm baby with *T. asahii* fungemia [16] recently reported severe thrombocytopenia, lethargy, feeding intolerance, bleeding manifestations in cases of *T. asahii* fungemia in preterm babies with low birth weight. Unexplained thrombocytopenia was again reported by John et al., [17] in an immunocompetent adult patient with *T. asahii* fungemia.

Treatment for invasive *Trichosporon* infections is still difficult and controversial. Few and variable data are available on the *in vitro* and *in vivo* activities of antifungal drugs against clinically relevant species of *Trichosporon*. In addition, the *in vitro* activity of antifungal drugs does not always correlate with good clinical response. Accordingly, No optimal therapy regimen for trichosporonosis has been identified. Amphotericin B has limited activity against *Trichosporon* species *in vitro* and *in vivo* while echinocandins are nearly not effective as a mono-therapy for invasive *Trichosporon* infections [18]

Triazoles are the drug of choice for antifungal treatment and *Trichosporon* infections in particular. Studies have shown that Voriconazole is highly active against *T. asahii* isolates *in vitro* and *in vivo*; including isolates with reduced susceptibility to Amphotericin B, Itraconazole, and Fluconazole. However, a case of breakthrough of *T. asahii* infection has been reported recently against Voriconazole [19].

Several studies and clinical trials have strongly recommended the use of combined antifungal synergistic therapy for *Trichosporon* infections as these combinations increase clinical efficacy e.g. the combination of Amphotericin B with Azoles and the combination of Echinocandins with Azoles or Amphotericin B [20]. In the present case, the treatment was initiated with failure by using a combination of Amphotericin B and Ketoconazole for 4 weeks. After that the treatment was replaced by a combination of Voriconazole and Caspofungin which eradicated *T. asahii* from the blood of the patient by the end of 2nd week of treatment.

Conclusion

We have described a rare case of *T. asahii* invasive infection in a low birth weight preterm newborn baby in the neonatal intensive care unit (NICU), Maternity and Children Hospital, Makkah, Saudi Arabia. *T. asahii* was isolated from the patient nasal swabs, groin swabs and then from blood cultures. No specific clinical manifestations could be detected on the preterm baby. Thrombocytopenia was the most prominent laboratory finding. This case of *T. asahii* fungemia was resistant to treatment with a combination of Amphotericin B and Fluconazole, However, the case was successfully treated using a combination of Voriconazole and Caspofungin.

Conflicts of Interest

All authors declare no conflict of interests in this work.

References

1. Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, et al. (2003) Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 22: 254-257.
2. Miceli MH, Diaz JA, Lee SA (2011) Emerging opportunistic yeast infections. Lancet Infect Dis 11: 142-151.
3. Colombo AL, Padovan AC, Chaves GM (2011) Current knowledge of Trichosporon spp. and Trichosporonosis. Clin Microbiol Rev 24: 682-700.
4. Ahmad S, Al-Mahmeed M, Khan ZU (2005) Characterization of Trichosporon species isolated from clinical specimens in Kuwait. J Med Microbiol 54: 639-46.
5. Falk R, Wolf DG, Shapiro M, Polacheck I (2003) Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole. J Clin Microbiol 41: 911.
6. Itoh T, Hosokawa H, Kohdera U, Toyazaki N, Asada Y (1996) Disseminated infection with Trichosporon asahii. Mycoses 39: 195e9.
7. Li H, Lu Q, Wan Z, Zhang J (2010) In vitro combined activity of amphotericin B, Caspofungin and Voriconazole against clinical isolates of Trichosporon asahii. Int J Antimicrob Agents 35: 550-552.
8. Miceli MH, Diaz JA, Lee SA (2011) Emerging opportunistic yeast infections. Lancet Infect Dis 11: 142-151.
9. Osoba AO, Al-Mowallad AW, McAlear DE, Hussein BA (2003) Candidemia and the susceptibility pattern of Candida isolates in blood. Saudi Med J: 1060-1063.
10. Vazquez JA (2010) Trichosporon infection. Curr Fungal Infect Rep 4: 52-58.
11. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, et al. (2002) In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother. 46: 1144-1146.
12. Al-Hedaithy SSA (2003) The yeast species causing fungemia at a university hospital in Riyadh, Saudi Arabia, during a 10-year period. Mycoses 46: 275-280.
13. Yamamoto M, Takakura S, Hotta G, Matsumura A, Matsushima A, et al. (2013) Clinical characteristics and risk factors of non-candida fungemia. BMC Infect Dis 13: 247.
14. Biasoli MS, Carlson D, Chiganer GJ, Parodi R, Greca A, et al. (2008) Systemic infection caused by Trichosporon asahii in a patient with liver transplant. Med Mycol 46: 719-23.
15. Pereira DN, Nader SS, Nader P, Martins PG, Furlan SP, et al. (2009) Disseminated Trichosporon spp infection in preterm newborns: a case report. J Pediatr (Rio J) 85: 459-461.
16. Basu S, Tilak R, Kumar A (2015) Multidrug-resistant Trichosporon: an unusual fungal sepsis in preterm neonates. Pathog Glob Health 109: 202-206
17. John R, Ebright, Marilyn R, Fairfax, Jose A (2001) Vazquez. Trichosporon asahii, a Non-Candida Yeast That Caused Fatal Septic Shock in a Patient without Cancer or Neutropenia. BRIEF REPORTS 33: P29.
18. Denning DW (2003) Echinocandin antifungal drugs. Lancet 362: 1142-1151.
19. Chen J, Chen F, Wang Y, Yang L, Miao M, et al. (2014) Use of combination therapy to successfully treat breakthrough Trichosporon asahii infection in an acute leukemia patient receiving Voriconazole. Medical Mycology Case Reports 6: 55-57.
20. Bassetti M, Bisio F, Di Biagio A, Pierri I, Balocco M, et al. (2004) Trichosporon asahii infection treated with Caspofungin combined with liposomal Amphotericin B. J. Antimicrob. Chemother 54: 575-577.

Citation: Bukhari MA, Abdelrazek SAM, El-Shalakany AH, Faiz A (2017) A *Trichosporon asahii* Bloodstream Infection in a Preterm Newborn with a Successful Outcome: A Case Report. J Blood Lymph 7: 157. doi: [10.4172/2165-7831.1000157](https://doi.org/10.4172/2165-7831.1000157)

OMICS International: Open Access Publication Benefits & Features

Unique features:

- Increased global visibility of articles through worldwide distribution and indexing
- Showcasing recent research output in a timely and updated manner
- Special issues on the current trends of scientific research

Special features:

- 700+ Open Access Journals
- 50,000+ Editorial team
- Rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at major indexing services
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.omicsonline.org/submission>